Oral diseases
-
Randomized Controlled Trial
Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: An open-label randomized trial.
This randomized open-label trial compared the efficacy and tolerability of vortioxetine (15 mg/daily) with different antidepressants in the treatment of patients with burning mouth syndrome (BMS). ⋯ Vortioxetine was efficacious with a shorter latency of action and fewer AEs compared with other ADs.